Several clinical trials have investigated the efficacy of CTLA-4 inhibitors alone (such as ipilimumab) or in combination with PD-1/PD-L1 inhibitors in NSCLC patients. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.